Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Position Reduced by Sei Investments Co.

Sei Investments Co. decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 30.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 98,338 shares of the company’s stock after selling 43,166 shares during the quarter. Sei Investments Co. owned 0.32% of Medpace worth $32,671,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in MEDP. Raymond James Trust N.A. increased its stake in Medpace by 34.6% during the third quarter. Raymond James Trust N.A. now owns 754 shares of the company’s stock valued at $252,000 after purchasing an additional 194 shares during the last quarter. Swedbank AB acquired a new position in shares of Medpace in the 3rd quarter valued at about $7,477,000. Centaurus Financial Inc. grew its position in shares of Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after buying an additional 29 shares during the last quarter. Fisher Asset Management LLC raised its stake in Medpace by 6.9% during the third quarter. Fisher Asset Management LLC now owns 124,399 shares of the company’s stock worth $41,524,000 after acquiring an additional 8,012 shares during the period. Finally, Independent Advisor Alliance lifted its holdings in Medpace by 16.7% in the third quarter. Independent Advisor Alliance now owns 941 shares of the company’s stock worth $314,000 after acquiring an additional 135 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MEDP. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Leerink Partnrs raised Medpace to a “hold” rating in a research report on Monday. Finally, Leerink Partners started coverage on Medpace in a research note on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Medpace has a consensus rating of “Hold” and an average price target of $376.30.

Medpace Trading Down 1.8 %

MEDP stock opened at $324.51 on Wednesday. The firm’s 50-day moving average is $337.16 and its two-hundred day moving average is $339.57. The company has a market capitalization of $9.89 billion, a price-to-earnings ratio of 25.69, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.